ANK-700 / Anokion, BMS - LARVOL DELTA

Preclinical Evidence that Liver-Targeted Antigen Therapies Induce Regulatory T-Cells and Control Immune Responses in Diseased Tissues and Result in Remission of Disease (ECTRIMS 2024) - "Introduction: ANK-700 is an investigational therapy composed of a liver-targeting glycosylation signature conjugated to a myelin antigen is being clinically evaluated for treatment of Multiple Sclerosis... These translatable data support that liver-targeted antigen is a viable approach to expanding antigen-specific Tregs in vivo and has therapeutic potential in a variety of inflammatory conditions, including indications such as Multiple Sclerosis where multiple antigens may be driving disease."

Preclinical • CNS Disorders • Diabetes • Immunology • Inflammation • Metabolic Disorders • Multiple Sclerosis • Type 1 Diabetes Mellitus

Safety, Tolerability, and Pharmacodynamic Assessment of ANK-700, a Novel Liver-Targeted Therapy to Induce Immunological Tolerance to Myelin Antigens in Relapsing-Remitting Multiple Sclerosis (ECTRIMS 2024) - "Single doses of ANK-700 up to 3.0 mg/kg and multiple doses up to 1.0 mg/kg were well tolerated and demonstrated trends toward tolerization with bystander suppression. Additional trials of this novel therapy are warranted."

Clinical • PK/PD data • CNS Disorders • Infectious Disease • Migraine • Multiple Sclerosis • Nephrology • Pain

Anokion Announces New Data from the Phase 1 MoveS-it Study Supporting ANK-700 as a Novel, Potential Disease Modifying Treatment for Relapsing-Remitting Multiple Sclerosis (Businesswire) - "Anokion SA...today announced data will be presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) being held September 18-20, 2024 in Copenhagen, Denmark. The abstracts include pre-clinical and new clinical data from Anokion’s Phase 1 MoveS-it study evaluating the safety and tolerability of ANK-700 in 34 patients between 18-60 years of age with relapse-remitting multiple sclerosis (RRMS) across the United States...Single doses of ANK-700 up to 3.0 mg/kg and multiple doses up to 1.0 mg/kg ANK-700 were shown to be safe and well tolerated with no Serious Adverse Events (SAEs) related to ANK-700 reported. Additionally, there was no clinical or magnetic resonance imaging (MRI) evidence of disease exacerbation."

P1 data • Preclinical • CNS Disorders • Immunology • Multiple Sclerosis

MoveS-it: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - P1 | N=33 | Completed | Sponsor: Anokion SA | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Multiple Sclerosis

Clinical And Preclinical Evidence that Liver-Targeted Antigen Therapies Induce Regulatory T Cells and Control Immune Responses in Diseased Tissues (IMMUNOLOGY 2024) - "Investigational therapies composed of a liver-targeting glycosylation signature conjugated to peptides are currently in clinical studies for treatment of both Celiac Disease (KAN-101) and Multiple Sclerosis (ANK-700). Liver-educated Tregs traffic to the site of inflammation, display a distinct phenotype and mediate bystander suppression. These data support that liver-targeted antigen is a viable approach to expand antigen-specific Tregs in vivo and has therapeutic potential in a variety of inflammatory condition, including indications where multiple antigens may be driving disease."

Preclinical • Celiac Disease • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • IL10 • IL2

MoveS-it: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - P1 | N=33 | Active, not recruiting | Sponsor: Anokion SA | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Multiple Sclerosis

MoveS-it: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: Anokion SA | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - P1; N=33; Recruiting; Sponsor: Anokion SA; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CNS Disorders • Multiple Sclerosis

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - P1; N=33; Not yet recruiting; Sponsor: Anokion SA

Clinical • New P1 trial • CNS Disorders • Multiple Sclerosis